Monte Rosa Therapeutics Inc GLUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $21.98
- Day Range
- $21.58–23.77
- 52-Week Range
- $4.12–25.77
- Bid/Ask
- $20.50 / $25.25
- Shares Outstanding
- 84.48M
- Market Cap
- $1.98B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 76.16
- Price/Sales
- 47.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 161
- Website
- https://www.monterosatx.com
Valuation
|
Metric
|
GLUE
|
|---|---|
Price/Earnings (Normalized) | 76.16 |
Price/Book Value | 3.79 |
Price/Sales | 47.77 |
Price/Cash Flow | — |
Price/Earnings
GLUE
Financial Strength
|
Metric
|
GLUE
|
|---|---|
Quick Ratio | 9.44 |
Current Ratio | 9.54 |
Interest Coverage | — |
Quick Ratio
GLUE
Profitability
|
Metric
|
GLUE
|
|---|---|
Return on Assets (Normalized) | −23.10% |
Return on Equity (Normalized) | −35.87% |
Return on Invested Capital (Normalized) | −35.99% |
Return on Assets
GLUE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zsn?X@H | LOCK|DqBg@ | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|msJ?>< | LOCK|>C^h | $70B | |||
| argenx SE ADR
ARGX
| LOCK|?K$x^RH | LOCK|$P | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!@^#Cn | LOCK|nm%VD | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mw&B^<! | LOCK|&& | $36B | |||
| Moderna Inc
MRNA
| LOCK|$!qxj%c | LOCK|DR | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|b>!f>lh | LOCK|NkB^ | $25B | |||
| Incyte Corp
INCY
| LOCK|k$D<gN | LOCK|zT | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|VMY<Kn | LOCK|Vc | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|>#zw^p | LOCK|^pD | $16B |
United States